ReviewRSC medicinal chemistry2023
Recent developments of imidazo[1,2-
Review in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 65 citations in OpenAlex.
- Imidazo[1,2‑ACS omega · 2026Review
- Development of Isoniazid-Pyrazole Hybrids as Potential Antitubercular Agents.International journal of molecular sciences · 2026Article
- Imidazo[1,2‑ACS omega · 2026Review
- Preparation of 3-(alkylamino)imidazo[1,2-Beilstein journal of organic chemistry · 2026Article
- Investigation of Potent Anti-Drug design, development and therapy · 2026Article
- Recent advances in magnetic nanocatalysts for synthesis of imidazo[1,2-RSC advances · 2025Review
- XAI-ACSM: An Ensemble-Based Explainable Artificial Intelligence Framework for the Accurate Prediction of Anticancer Small Molecules.ACS omega · 2025Article
- Molecular structure, DFT computations, and docking studies of an imidazo[1,2-a]pyridine derivative containing 1,2,3-triazole and 4-bromophenyl moieties.Journal of computer-aided molecular design · 2025Article
- Recent Advances in Visible Light-Induced C-H Functionalization of Imidazo[1,2-a]pyridines.Molecules (Basel, Switzerland) · 2025Review
- Multicomponent reactions (MCRs) yielding medicinally relevant rings: a recent update and chemical space analysis of the scaffolds.RSC advances · 2025Review
- Microwave-assisted Green Synthesis: An Approach for the Development of Anti-tubercular Agents.Current drug targets · 2025Review
- An ESIPT-active orange-emissive 2-(2'-hydroxyphenyl)imidazo[1,2-RSC advances · 2024Article
- CMolecules (Basel, Switzerland) · 2024Article
- Imidazopyridine Family: Versatile and Promising Heterocyclic Skeletons for Different Applications.Molecules (Basel, Switzerland) · 2024Review
- Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.ACS medicinal chemistry letters · 2024Article
- Activity againstRSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 2000 years, tuberculosis (TB) has killed more people than any other infectious disease. In 2021, TB claimed 1.6 million lives worldwide, making it the second leading cause of death from an infectious disease after COVID-19. Unfortunately, TB drug discovery research was neglected in the last few decades of the twentieth century. Recently, the World Health Organization has taken the initiative to develop new TB drugs. Imidazopyridine, an important fused bicyclic 5,6 heterocycle has been recognized as a "drug prejudice" scaffold for its wide range of applications in medicinal chemistry. A few examples of imidazo[1,2-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.